Jack W. Callicutt
2021
In 2021, Jack W. Callicutt earned a total compensation of $705.9K as Chief Financial Officer at Galectin Therapeutics, a 2% decrease compared to previous year.
Compensation breakdown
| Bonus | $90,630 |
|---|---|
| Option Awards | $235,126 |
| Salary | $302,100 |
| Other | $78,062 |
| Total | $705,918 |
Callicutt received $302.1K in salary, accounting for 43% of the total pay in 2021.
Callicutt also received $90.6K in bonus, $235.1K in option awards and $78.1K in other compensation.
Rankings
In 2021, Jack W. Callicutt's compensation ranked 9,867th out of 12,415 executives tracked by ExecPay. In other words, Callicutt earned more than 20.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,867 out of 12,415 | 21st |
Division Manufacturing | 4,366 out of 5,508 | 21st |
Major group Chemicals And Allied Products | 1,945 out of 2,378 | 18th |
Industry group Drugs | 1,727 out of 2,099 | 18th |
Industry Pharmaceutical Preparations | 1,287 out of 1,549 | 17th |
Source: SEC filing on October 17, 2022.
Callicutt's colleagues
We found two more compensation records of executives who worked with Jack W. Callicutt at Galectin Therapeutics in 2021.
News
Galectin Therapeutics CEO Joel Lewis' 2023 pay slips 1% to $964K
December 3, 2024
Galectin Therapeutics CEO Joel Lewis' 2022 pay slips 17% to $974K
October 6, 2023
Galectin Therapeutics CEO Joel Lewis' 2021 pay jumps 55% to $1.2M
October 17, 2022
Galectin Therapeutics CEO Harold Shlevin's 2019 pay falls 25% to $1.3M
October 19, 2020